Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03628066 · ClinicalTrials.gov registry record · Phase 2

Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer

A Phase 2 study of Breast Cancer, sponsored by NSABP Foundation.

Completed
Registry status
Phase 2
Development phase
24
Enrollment target
15
Study locations

NCT03628066 is a Phase 2 study of Breast Cancer that has completed, run by NSABP Foundation. The registered enrollment target is 24 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 15 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03628066, a Phase 2 study of Breast Cancer, has completed, sponsored by NSABP Foundation.

COMPLETED
Registry status
Phase 2
Development phase
24 participants
Enrollment target
15
Study locations

Study Summary

This study will look at the safety and effectiveness of the combination of palbociclib and letrozole and ovarian suppression for premenopausal patients who have ER-positive/HER2-negative breast cancer that has not yet been treated.

Conditions Studied

Breast Cancer

Interventions

  • DRUG Letrozole
  • DRUG Palbociclib
  • DRUG Goserelin
  • DIAGNOSTIC_TEST Oncotype DX Breast Recurrence Score

Study Locations (15)

California

  • Breast Cancer Care Specialist - Fountain Valley
  • Orange Coast Blood and Cancer Care - Fountain Valley
  • Saddleback Memorial Medical Center - Laguna Hills
  • Coast Hematology-Oncology Associates Medical Group - Long Beach
  • Long Beach Memorial Medical Center - Long Beach
  • Oncology Hematology Consultants - Long Beach

Quebec

  • Centre Hospitalier de l'Universite de Montreal - Montreal
  • Jewish General Hospital - Montreal - Montreal
  • McGill University Health Centre-Cedars Cancer Centre - Montreal
  • CHU de Quebec - Hopital de Saint-Sacrement - Québec

Illinois

  • Cancer Care Specialists of Central Illinois - Decatur

South Dakota

  • Avera Cancer Institute-Sioux Falls - Sioux Falls

Texas

  • Lester and Sue Smith Breast Center - Houston

West Virginia

  • West Virginia University - Morgantown

Wisconsin

  • Froedtert Hospital - Milwaukee

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2018-10-22
Est. Completion 2021-01-30
Phase Phase 2

Sponsor

NSABP Foundation

44 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03628066

The ClinicalTrials.gov registry entry for NCT03628066 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The listed sponsor is NSABP Foundation, which has 44 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 4 interventions - of which Letrozole is the first listed.

NCT03628066 reports 15 study locations spanning 7 distinct geographic areas - top geographies include California, Quebec, Illinois.

Frequently Asked Questions

What is clinical trial NCT03628066 about?

NCT03628066 is a clinical study titled "Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer". This study will look at the safety and effectiveness of the combination of palbociclib and letrozole and ovarian suppression for premenopausal patients who have ER-positive/HER2-negative breast cancer that has not yet been treated.

What is the current status of trial NCT03628066?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2018-10-22. Estimated completion is 2021-01-30.

What conditions does trial NCT03628066 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT03628066?

The interventions under investigation include: Letrozole (DRUG), Palbociclib (DRUG), Goserelin (DRUG), Oncotype DX Breast Recurrence Score (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT03628066?

This trial is sponsored by NSABP Foundation, which has 44 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03628066 being conducted?

This trial has 15 study locations across California, Illinois, South Dakota, Texas, West Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.